Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 billion in cash to help bolster its arsenal of cancer drugs. Turning Point’s lead drug, repotrectinib, targets mutations in certain proteins in the body that lead to unchecked cell growth. Bristol Myers will pay $76 per Turning…
Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal
Bristol Myers Drug Wins First US Approval for Graft Versus Host Disease Prevention
Bristol Myers Squibb Co.’s Orencia on Wednesday became the first drug to win U.S. approval for the prevention of acute Graft versus Host Disease (aGvHD), a potentially fatal complication that could occur after a stem cell transplant. The Food and Drug Administration (FDA) has cleared the drug in combination with certain immunosuppressants for use in…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`